help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-2377
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/6/3773    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matyakhina, L.
Right arrow Articles by Stratakis, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matyakhina, L.
Right arrow Articles by Stratakis, C. A.
Related Collections
Right arrow Adrenal and Hypertension
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 6 3773-3779
Copyright © 2005 by The Endocrine Society


CLINICAL CASE SEMINAR

Hereditary Leiomyomatosis Associated with Bilateral, Massive, Macronodular Adrenocortical Disease and Atypical Cushing Syndrome: A Clinical and Molecular Genetic Investigation

Ludmila Matyakhina1, Reneé J. Freedman1, Isabelle Bourdeau, Ming-Hui Wei, Sotirios G. Stergiopoulos, Aaron Chidakel, McClellan Walther, Mones Abu-Asab, Maria Tsokos, Meg Keil, Jorge Toro, W. Marston Linehan and Constantine A. Stratakis

Section on Genetics and Endocrinology (L.M., R.J.F., I.B., S.G.S., M.K., C.A.S.), Developmental Endocrinology Branch, and Inter-Institute Endocrinology Training Program (R.J.F., A.C., C.A.S.), National Institute of Child Health and Human Development; Program of Division of Cancer Epidemiology and Genetics, SAIC-Frederick, Inc., Frederick (M.-H.W.); Urologic Oncology Branch (M.W., W.M.L.); and Section on Electron Microscopy (M.A.-A., M.T.), Laboratory of Pathology, and Epidemiology Branch (J.T.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: Dr. Constantine A. Stratakis, Section on Endocrinology and Genetics, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Building 10, Clinical Research Center, Room I-3330 (East Laboratories), 10 Center Drive, MSC 1103, Bethesda, Maryland 20892. E-mail: stratakc{at}mail.nih.gov.

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant disorder caused by mutations in the fumarate hydratase (FH) gene on chromosome 1q42.3–43. Massive macronodular adrenocortical disease (MMAD) is a heterogeneous condition associated with Cushing syndrome (CS) and bilateral hyperplasia of the adrenal glands. In MMAD, cortisol secretion is often mediated by ectopic, adrenocortical expression of receptors for a variety of substances; however, to date, no consistent genetic defects have been identified. In a patient with HLRCC caused by a germline-inactivating FH mutation, we diagnosed atypical (subclinical) CS due to bilateral, ACTH-independent adrenocortical hyperplasia. A clinical protocol for the detection of ectopic expression of various hormone receptors was employed. Histology was consistent with MMAD. The tumor tissue harbored the germline FH mutation and demonstrated allelic losses of the 1q42.3–43 FH locus. We then searched the National Institutes of Health (NIH) databases of patients with MMAD or HLRCC and found at least three other cases with MMAD that had a history of tumors that could be part of HLRCC; among patients with HLRCC, there were several with some adrenal nodularity noted on computed tomography but none with imaging findings consistent with MMAD. From two of the three MMAD patients, adrenocortical tumor DNA was available and sequenced for coding FH mutations; there were none. We conclude that in a patient with HLRCC, adrenal hyperplasia and CS were due to MMAD. The latter was likely due to the FH germline mutation because in tumor cells, only the mutant allele was retained. However, other patients with MMAD and HLRCC, or HLRCC patients with adrenal imaging findings consistent with MMAD, or MMAD patients with somatic FH mutations were not found among the NIH series. Although a fortuitous association cannot be excluded, HLRCC may be added to the short list of monogenic disorders that have been reported to be associated with the development of adrenal tumors; FH may be considered a candidate gene for MMAD.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
F. Weber and C. Eng
Update on the Molecular Diagnosis of Endocrine Tumors: Toward -omics-Based Personalized Healthcare?
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1097 - 1104.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society